The idea for VA’s Close To Me Infusion Service has its roots in many places, One of them a veteran that Jenna Shields, PharmD, BCOP, saw weekly at the Pittsburgh VAMC.
Military Healthcare Beneficiaries Have Better NSCLS Survival.
Does the universal healthcare provided by the U.S. military health system (MHS) mean better lung cancer survival for patients? A new study suggested that is the case.
Real-World Pneumonitis Rates After Chemotherapy Plus Durvalumab
ANN ARBOR, MI – While adjuvant durvalumab after definitive chemoradiotherapy (CRT) for unresectable stage III non-small cell lung cancer (NSCLC) is well-tolerated in clinical trials, that is not always the case in the real-world, according to a new VA study....
NSCLC Survival Rates Higher with Distant Recurrence vs. De Novo Metastasis
PALO ALTO, CA – Even with new and improved therapies, clinicians remain challenged by how to deal with advanced lung cancer. “The survival profile of patients with metastatic lung cancer remains poorly understood by metastatic disease type (i.e., de novo stage IV vs....
Biomarkers Predict Survival, Risk of Adverse Effects in Metastatic NSCLC
ANN ARBOR, MI – Lung cancer outcomes have been significantly improved with the use of immune checkpoint inhibitors (ICI), although some patients derive only limited benefit from the therapy and others experience potentially serious toxicities. That’s why a new study...
No Racial Differences in DLBCL Treatment Within VA Healthcare System
No statistically significant racial differences in diffuse large B-cell lymphoma (DLBCL) outcomes were found for patients treated within the VHA, according to recent research.
Very Elderly Patients Fare Much Worse When Treated for DLBCL
Diffuse large B-cell lymphoma (DLBCL) becomes much more difficult to treat in older patients, according to a new study suggesting that more adults of advanced age be included in clinical trials for new agents.
Despite Disparities, Making a Difference for Veterans With Relapsed DLBCL
DURHAM, NC—Recent Food and Drug Administration approvals of chimeric antigen receptor (CAR) T cell therapies and novel immunotherapies have helped to significantly improve outcomes for patients with relapsed and refractory diffuse large B cell lymphoma (R/R DLBCL)....
More Diverse Dataset Raises Questions about MGUS Risk Models
Patients with monoclonal gammopathy of undetermined significance (MGUS) have been thought to have a less than 1% chance of progressing to multiple myeloma as long as their M-protein levels are below 1.5 g/dL.
Lower Relapse Rates Suggest Limited Value for Prophylaxis in DLBCL
Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) relapse or progress following first-line chemoimmunotherapy.
For CLL, BTK Inhibitors Appear to Extend Time to Next Line Most
JACKSONVILLE, FL—As treatment options for chronic lymphocytic leukemia (CLL) multiply, physicians face an increasing array of sequencing options but have little guidance from clinical trials of the most effective order given each patient’s specific disease...
MGUS Higher in Servicemembers, No Association Seen With Burn Pit Exposure
Individuals who have served in the U.S. military have about three times the risk of monoclonal gammopathy of undetermined significance (MGUS) as a similarly aged cohort in the Icelandic iStopMM study.
Mental Health Issues Increase Mortality in Some Veterans With AML
Venetoclax combinations are common treatments for individuals with acute myeloid leukemia (AML) who are unable to withstand the rigors of intensive induction chemotherapy.
BTK Inhibitors Provide Option for CLL Patients With Severe Renal Dysfunction
BTK inhibitors have proven to be a powerful tool in CLL treatment and have replaced chemoimmunotherapy as the preferred first-line treatment.
Evaluate Veterans With MGUS for Cardiovascular Disease
Monoclonal gammopathy of undetermined significance (MGUS) is not considered a hematological condition of concern, yet it is associated with lower overall survival. VA researchers led by Lawrence Liu, MD, of the St. Louis VAMC, explored whether the reduced life expectancy arose from an increased risk of cardiovascular events.
Deployment Linked to Longer Survival in Servicemembers, Veterans With NHL
A study presented at the 2023 ASH Conference, provided additional evidence for the healthy deployer effect, this time in individuals with non-Hodkin lymphoma.
Which Veterans Should Undergo SPEP Testing for Plasma Cell Dyscrasia?
Plasma cell dyscrasia affects up to 5% of adults. While often asymptomatic, its characteristic clonal expansion of bone marrow plasma cells can also indicate the presence of several hematological malignancies including multiple myeloma.
GLP-1 Use Reduces Risk of MGUS Progression in Some Veterans
Glucagon-like peptide 1 (GLP-1) receptor agonists have gained huge popularity as they have demonstrated the ability to substantially reduce both blood-glucose levels and weight. In addition, recent research suggests cardiovascular and renal benefits to their use in certain populations.
Agent Orange Increases CVD Risk in Veterans With Myeloproliferative Neoplasms
As Vietnam-era veterans move into the age range in which most myeloproliferative neoplasms (MPNs) develop, the VA has a keen interest in fully understanding the full impact of exposure to Agent Orange in veterans with these malignancies.
Thrombosis Risk With Cancer Treatment Varies With VA Patient Characteristics
Has cancer-directed therapy changed patterns of the incidence and risk of cancer-associated thrombosis (CAT) at the VA?
High Serum TARC Levels Predict Hodgkin Lymphoma Years Before Diagnosis
Could high levels of the chemokine TARC produced in tumor cells in classic Hodgkin lymphoma help predict the malignancy?
CLL Patients at the VA Receive Evidence-Based Treatments
Chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) are the most common forms of adult leukemia. More than 13,000 veterans have the diagnosis, which is associated with the toxic exposures included in the Pact Act, according to the VA.
B-cell lymphoma Presenting With Cranial Nerve Palsy, Mononeuritis Multiplex
Diagnosing B-cell lymphoma-associated mononeuritis multiplex, a peripheral neuropathy, can be challenging because of its rarity and the potential co-existence of other causes of the symptoms.
Older Age of DLBCL Patients Makes Treatment Challenging
Nearly one-half (49%) of all veterans in the United States are 65 years or older. Most of those older veterans (5.5 million) served during the Vietnam era, while 183,000 were World War II veterans, according to the 2021 American Community Survey (ACS).
High Serum TARC Levels Predict Hodgin Lymphoma Years Before Diagnosis
A study found that TARC levels measured in pre-diagnostic serum samples had notably increased values in most patients up to over six years before diagnosis.
Lymphoma Most-Common Cancer Diagnosed in Active-Duty Military Personnel
SAN ANTONIO –Active-duty servicemembers diagnosed with lymphoma within the MHS had better overall survival than a matched civilian cohort, but the authors of a study with that finding emphasized that more information is needed to ensure optimal treatment for those...
VA Will Assess Leukemias, Multiple Myeloma as Presumptive Service Conditions
In what could be the first conditions added to the new PACT Act, the VA is conducting a scientific review to determine any relationship between three conditions—acute leukemias, chronic leukemias, and multiple myeloma outside of the head and neck—and toxic exposures for servicemembers who deployed to Iraq, Afghanistan, Somalia, Djibouti, Egypt, Jordan, Lebanon, Syria, Yemen, Uzbekistan, and the entire Southwest Asia theater of operations.
Multiple Myeloma Unusual in Younger Patients, Behaves Differently
Multiple myeloma (MM) is extremely unusual in adolescents and young adults (AYAs) younger than 45, and, when it does occur, often has some unusual features.
Better Gauging Breast Cancer Risk in Women Veterans of African Ancestry
Polygenic risk scoring (PRS) appeared to work well in predicting incident breast cancer for a prospective cohort of European (EUR) ancestry women veterans but not as well for those of African ancestry, according to a recent study.
Chemotherapy-Free Option Could Be Viable for Some Metastatic Breast Cancer
VA and MHS are treating far more breast cancer than ever before, especially since some recent studies suggest that women veterans are as much as 40% more likely to develop breast cancer than their civilian counterparts.
